STOCK TITAN

Connect Biopharma Holdings (CNTB) Stock News, Sep 2023-Apr 2024

CNTB NASDAQ

Connect Biopharma Holdings Limited reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on inflammatory diseases. Its principal program is rademikibart, an antibody designed to target interleukin-4-receptor alpha, with company updates centered on asthma, chronic obstructive pulmonary disease and moderate-to-severe atopic dermatitis.

Recurring news includes rademikibart clinical data, Seabreeze STAT asthma and COPD study updates, Data Monitoring Committee and regulatory-related disclosures, partner activity involving Simcere in China, financial results, financing activity, investor conference participation and governance matters.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.40%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.83%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.83%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none

FAQ

What is the current stock price of Connect Biopharma Holdings (CNTB)?

Connect Biopharma Holdings (CNTB) last closed at $0.6772.

What is the market cap of Connect Biopharma Holdings (CNTB)?

The market cap of Connect Biopharma Holdings (CNTB) is approximately $42.6M.